Halozyme Therapeutics (HALO) approves $750M share repurchase program

December 9, 2021 4:01 PM EST Send to a Friend
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its Board of Directors has approved a new share repurchase program ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login